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Protein microarray technology provides a versatile platform for characterization of hundreds to 
thousands of proteins in a parallel and high-throughput manner. Over the last decade, applications of 
functional protein microarrays in particular have flourished in studying protein function at a systems 
level and has led to the construction of networks and pathways describing these functions. Relevant 
areas of research include the detection of various binding properties of proteins, the study of enzyme-
substrate relationships, the analysis of host-microbe interactions, and profiling antibody specificity. In 
addition, discovery of novel biomarkers in autoimmune diseases and cancers is emerging as a major 
clinical application of functional protein microarrays. The Zhu lab used a protein microarray-based 
approach to systematically survey the entire human transcription factor (TF) family and found 
numerous purified TFs exhibit specific binding activity to methylated and unmethylated DNA motifs 
of distinct sequences. DNA methylation, especially CpG methylation at promoter regions, has been 
generally considered as a potent epigenetic modification that prohibits (TF) recruitment, resulting in 
transcription suppression. To elucidate the underlying mechanism, we focused on Kruppel-like factor 4 
(KLF4), and decoupled its mCpG- and CpG-binding activities via site-directed mutagenesis. This 
study suggested that mCpG-dependent TF binding activity is a widespread phenomenon and provides a 
new framework to understand the role and mechanism of TFs in epigenetic regulation of gene 
transcription 
 
Further studies from the Xia Lab showed that KLF4 promotes cell adhesion, migration, and 
morphological changes, all of which are abolished by a single mutation in R458 to an alanine. 
Surprisingly, 116 genes are directly activated via mCpG-dependent KLF4 binding activity. These 
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studies demonstrate a new paradigm of DNA methylation-mediated gene activation and chromatin 
remodeling, and provides a general framework to dissect the biological functions of DNA methylation 
readers and effectors. 
 
My thesis project focused on characterizing the KLF4 methylation dependent migration targets 
identified in previous studies. UDP-Glucose 6-dehydrogenase (UGDH) was identified as one of the 
downstream targets of KLF4-mCpG binding activity. This work shows that KLF4 upregulates UGDH 
expression in a mCpG-dependent manner, and UGDH is required for KLF4 induced cell migration in 
vitro. UGDH produces UDP-α-D-glucuronic acid, the precursors for glycosaminoglycans (GAGs) and 
proteoglycans (PGs) of the extracellular matrix. Elevated GAG formation has been implicated in a 
variety of human diseases, including glioblastoma (GBM). UGDH knockdown decreases 
glycosaminoglycan (GAG) abundance in GBM cells, as well as cell proliferation and migration in 
vitro. In intracranial xenografts, reduced UGDH inhibits tumor growth and decreases expression of 
extracellular matrix, e.g. tenascin C, brevican. These studies demonstrate a novel DNA methylation-
dependent UGDH upregulation by KLF4. Developing UGDH antagonists to decrease the synthesis of 
extracellular matrix components will be a useful strategy for GBM therapy. Further studies of KLF4 
mCpG interaction revealed a novel KLF4 binding to enhancer regions to regulate transcription such as 
the BLK gene. Through Chromosome Conformation Capture (3C) analysis, we found BLK was 
activated by KLF4 binding to enhancers in a methylation dependent manner. In addition, we found that 
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1.1 Introduction   
The protein microarray has revolutionized high-throughput biology by allowing researchers to 
simultaneously interrogate biochemical function of hundreds of thousands of proteins arrayed at high 
density on a solid surface. In addition to being a highly parallel platform, protein microarrays are 
capable of detecting interactions and modifications to femtomole quantities of protein, reduce 
experiment-to-experiment variability, and require minimal sample input, making this technique a 
powerful tool appropriate for clinical and basic research. Protein microarrays can be categorized into 
three major groups: analytical, functional, and reverse phase.  Functional protein microarrays are 
constructed from purified proteins or protein fragments encoded by an organism for biochemical 
assays to characterize binding interactions, modification, or enzymatic activity of proteins printed on 
the array [1]. Analytical microarrays utilize affinity reagents, most often antibodies, to detect and/or 
quantify a large number of proteins presented in a complex biological sample [2]. Conversely, reverse 
phase protein microarrays expand the applications of classical protein microarrays by spotting many 
complex mixtures, such as cell/tissue lysates or serum samples, directly on the surface of the slide and 
probes with specific binding characteristics can be used to identify components within each mixture 
[3].  
Applications with functional protein microarrays in particular have dramatically expanded over the 
past decade. In this review, we will highlight the design and methodology of high-throughput screens 
with functional protein microarrays and summarize applications and recent achievements within the 






1.2 Design and Fabrication of Functional Protein Microarrays  
When designing experiments with functional protein microarrays for high-throughput screens, it is 
essential that individually purified proteins of full-length are used, and that they remain in their native 
conformation once printed on the array surface. In addition, choosing a proper detection method and 
surface chemistry is crucial to the success of an assay because both can affect the outcome of the 
results. After each of these factors has been considered, functional protein microarrays can be 
fabricated for a variety of applications, which will be discussed in the next section [4]. 
Protein Production  
Generating proteins necessary for high-content functional protein arrays presents a significant 
technical barrier and often calls for the parallel purification of hundreds to thousands of proteins. This 
is further complicated by the need for relatively large amounts of pure proteins with the correct post-
translational modifications and conformation to produce active proteins. Recent endeavors in both 
industry and academia have applied a variety of ingenuities in vitro and in vivo expression/purification 











Table 1: High-Content Functional Protein Microarrays 
Name of Array No. of proteins Proteome 
Coverage 
Company/Lab Group References 
HuProt (Human) 19,394  ~80% CDI Laboratories, Zhu Lab [1-3]  






N/A Uhlen Lab  [7-9] 










~15% Labaer Lab 
 
[15-17]  
M. tuberculosis 4,262  >98% BC-Bio, Tao Lab [18] 
E. coli (K12) 4,256 >98% Zhu/Chen Labs [19] 
Herpesviridae  (HSV-
1, EBV, KSHV, 
HCMV) 
350  N/A Zhu/Hayward Labs [20] 
Pathogens Antigen 
(Various Species) 
200 - 4,000 N/A Antigen Discovery Inc., 
Felgner Lab 
[21-24] 
Influenza Array  127  N/A Carter Lab [25] 
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Surface Chemistry  
Once a library has been constructed, proteins can be immobilized onto a functionalized surface or 
slide. These surfaces can consist of reactive groups that form covalent linkages with spotted proteins, a 
3-dimensional matrix restricting protein movement, or affinity reagents that form a strong interaction 
with some component of the printed proteins (Table 2) [4]. Maintaining protein integrity and activity is 
essential; as a result, the benefits and shortcomings of each surface chemistry should be considered 
before selecting the method most appropriate for the desired application.  
 
Table 2: Surface Chemistry for Protein Immobilization 


















Covalent Aldehyde, Epoxy, NHS, 
carboxylic ester, etc. 
Permanent attachment, low 
background 
Random orientation, 
low binding capacity 
Affinity 
Capture 
Streptavidin, Ni+2 NTA, 
Glutathione, Sortase (Gly3) 
Uniform orientation, 
strong/specific attachment 
Must have domains or 
tags (e.g., biotin) 







The use of radioisotope- or fluorescently-labeled probes is the most common means of detecting 
biological interactions and reactions (Figure 2). Such label-dependent detection is straight-forward and 
simple to apply to most assays; however, these end-point measurements are not amendable to 
determination of kinetic parameters and requires labeling a probe-of-interest/cofactor, or use of affinity 
reagents to detect signal. To minimize perturbation to biological samples, a number of label-free 
detection platforms have been developed or adapted to the protein microarray format, including mass 
spectrometry, surface plasmon resonance (SPR), and oblique incidence reflectivity difference (OIRD) 
[5,6,7,8,9]. Photonic crystal (PC)-based detection is another emerging sensitive label-free detection 
method that functions by measuring small changes in refractive index of pores embedded on the 
surface of a silicon wafer to monitor binding interactions [10-12]. An additional benefit of OIRD, PC, 
and SPR is that binding interactions can be monitored in real-time allowing for the association and 
dissociation rate constants, kon and koff, to be calculated. These rate constants give a more complete 
picture of binding interactions than the dissociation equilibrium constant, Kd, as multiple values of kon 







Figure 1-1: Detection Methods for Protein Microarrays 
Label-dependent detection of protein interactions and modification is the most common (Top panel) 
[26]. Label-free detection methods do not require that proteins be modified; consequently, protein will 
have native conformation and is amendable to real-time kinetic monitoring (Bottom panel) [27-31]. 




1-3. Applications in Basic Research 
Array-based approaches have been powerful tools for protein expression profiling, biomarker 
discovery, post-translational modification study, and the examination of interactions with protein, 
DNA, RNA, peptide and small molecules. A typical large-scale project usually begins with a 
biological question, which dictates the design of the biochemical assays performed on a functional 
protein microarray (Figure 1-1, left panel). The power of the protein microarray is derived from the 
near-comprehensive, unbiased screening of a proteome. The resulting datasets are then processed with 
sophisticated bioinformatics tools to reveal otherwise hidden biological functions, based on which a 
new hypothesis may be generated. Finally, orthogonal in vitro and in vivo assays are performed to test 
the hypothesis.  
Using Protein Microarrays to Characterize Protein-Nucleic Acid Interactions  
Characterization of protein-nucleic acid interactions is essential for understanding regulation of genes 
and protein expression within the cell and is the focus of international collaborations such as the 
Encyclopedia of DNA Elements (ENCODE) [13]. Protein microarrays can play a vital role in the 
elucidating the molecule mechanisms responsible for the sophisticated regulation within cells [14]. For 
example, in one of our recent projects we questioned whether a large number of human transcription 
factors (TFs) existed that preferentially recognize methylated CpG (mCpG)-containing DNA motifs 
[15]. We designed a competition-based assay to identify preferential methylated DNA-binding by 
probing 154 methylated DNA motifs to our human TF protein microarrays. Bioinformatic analysis 
revealed that 47 TFs and co-factors could preferentially bind to methylated DNA motifs; 17 of them 
recognized both methylated and unmethylated motifs of very different sequences. This led us to 
hypothesize that some human TFs could recognize methylate promoters to activate transcription in 
cells. Further validation demonstrated that one of the 17 TFs, KLF4, binds to methylated promoters in 
human embryonic stem cells and such mCpG-dependent binding activity could activate downstream 
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gene transcription. Functional protein microarrays can be employed to identify novel protein 
interactions with coding- and non-coding RNA representing additional control and regulation within 
the cell [16].  
Post-Translational Modifications 
Protein posttranslational modifications (PTMs) play an important role in regulating protein activity, 
stability, and/or subcellular localization. Among the hundreds of PTMs identified so far, enzyme-
dependent, reversible protein phosphorylation, ubiquitylation, SUMOylation, acetylation, and 
glycosylation are the best studied. The importance of creating systematic network maps of enzyme-
substrate relationships is emphasized by the layered nature of protein regulation in biological 
machinery; the activity of modifying enzyme are frequently themselves controlled by PTMs. By 
performing phosphorylation reactions on human protein microarrays and integrating the existing 
phosphorylome datasets, Newman et al. were able to construct an activity-based human 
phosphorylation network that connects a kinase not only to its substrate(s), but also to a particular 
phosphorylated residue [17-20]. Such large-scale analysis of enzyme-substrate relationships is being 
expanded to study ubiquitylation, acetylation, and glycosylation and will be increasingly valuable as 
protein-localization data becomes available and further modifying enzymes are profiled [20-24].  
 10 
 
Figure 1-2 Applications of Protein Microarrays 
Outline of scientific approach using functional protein microarrays. A protein microarray screen can be designed 
to near-comprehensively interogate proteomes in an unbiased manner to answer biological questions. Results 
from initial screen are processed using statistical analysis and orthogonal validations (Left panel). Screens on the 
protein microarray can identify protein interactions, modifications, and proteins of interest for biomarker 





1-4. Applications in Clinical Research  
Biomarker Discovery 
Biomarkers are detectable signatures that can serve as diagnostic tools in the clinical setting, and can 
facilitate vaccine and drug development in basic research. For instance, upon infection by a deleterious 
pathogen the immune system will respond and develop antibodies against a foreign agent. These 
antibodies become the hallmark of infection and allow for detection of the history of exposure to a 
pathogen. Researchers can view proteins on a functional protein microarray as antigens to accelerate 
biomarker discovery by identifying antibodies that statistically correlate with the disease of interest. 
Zhu and colleagues reported the first protein microarray-assisted serological study to identify Severe 
acute respiratory syndrome (SARS) infected patients in China and Canada [25]. Following this study, 
many new pathogen protein/antigen microarrays have been established, including malaria 
(Plasmodium), HIV-1, influenza, herpesviruses, and tuberculosis [26-34].  
Biomarker identification is not limited to pathogens; diagnosis of many human diseases, especially 
autoimmune diseases and cancers, is challenging and often relies on pathological tests [35,36]. Hudson 
et al. used a functional protein microarray consisting of 5,005 human proteins to screen patient 
autoantibodies and discovered antigens useful for ovarian cancer diagnosis [37]. In 2009, Song et al. 
developed a cost-effective, streamlined two-stage screening approach for biomarker identification in 
autoimmune hepatitis (AIH) [4,38]. In the first stage, a human protein microarray with ~5,000 proteins 
was probed with a small cohort of patient sera to identify 11 candidate autoantigens. In the second 
stage, these candidates were printed in 12 duplicate blocks on the microarray surface to allow for 
groups of 12 patient serum samples from a larger cohort to be simultaneously profiled with a single 
array. Three of the candidates were confirmed as AIH biomarkers by bioinformatic analysis and 
validated with further experiments. These studies demonstrate the utility and versatility of functional 
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protein microarrays as a diagnostic and basic research tool in clinical applications and will continue to 
improve as the technology matures [39,40]. 
 
1-5. Conclusions 
Functional protein microarrays, especially those of high-content, and their applications have evolved 
significantly since the first proteome microarray was introduced in 2001 by Zhu et. al [1]. These 
successes capitalize on femtomolar sensitivity for profiling full proteomes in high-throughput yet 
straightforward assays. We have described their utility for a myriad of applications that have resulted 
in impactful scientific findings, ranging from discovery of mCpG-dependent DNA-binding activity 
among human transcription factors to construction of kinase-substrate relationship networks, and 
biomarker discovery. While protein microarrays leverage the advantage of uniform protein sampling 
and high sensitivity, for proteomics, their impact is limited by the extent of coverage for different 
species. To this end, many research groups and companies have begun expanding the availability of 
high-content proteome arrays (Table 1). A remarkable advance was put forth by the Zhu laboratory 
with the construction of the first human proteome microarray containing over 17,000 full length 
proteins representing ~75% of the human proteome and is the largest available to date [15,39].  From a 
technological point of view, more reliable and higher density protein arrays are becoming more readily 
available (Table 1)   
Despite these milestones, significant improvement can still be made. Transmembrane proteins, 
representing ~26% of the human proteome, are the preferred targets of nearly 70% of all drugs [41]. 
However, these proteins, especially those containing multipass transmembrane domains, are 
notoriously difficult to study because they must be embedded in a membrane to maintain their native 
conformation and many require proper post-translational modifications (PTMs) to be functional [42]. 
To overcome these hurdles, we recently developed Virion Display (VirD) technology through which 
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human transmembrane proteins could be assayed in their native conformation in microarray format. 
The unique advantages of this approach is that a human transmembrane protein is embedded in the 
viral envelop of Herpes Simplex Virus 1 (HSV-1) in a correct orientation with proper PTMs [42]. The 
VirD Array is expected to be readily transformed to a high-content platform that can display virtually 
all of the human membrane proteins close to their native conformation on a single glass slide.  
 
The capabilities of microarray technology are further expanding with the development of label-free 
detection methods that are capable of monitoring the kinetics of biomolecular interactions in real time.  
By observing molecular reactions in real time, OIRD, SPR, and PC are capable of determining the 
kinetic parameters kon and koff [5,7,10]. In 2015 Liu et. al demonstrated the ability of the OIRD to 
simultaneously determine these parameters for multiple monoclonal antibodies [7]. 
Lastly, there is an increasing trend in the use of protein microarray technology for biomarker 
discovery. Human diseases leave a characteristic fingerprint on the proteome through alterations to 
expression and PTMs. Experiments performed by Woodard et al. have demonstrated that functional 
protein microarrays can identify differentially phosphorylated proteins using xenograft tumor and cell 
lysates [43]. Consequently, protein microarray arrays are poised to promote discovery of novel 
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2-1. DNA Methylation  
DNA methylation at the 5 position of the cytosine base (5mC) is the primary epigenetic modification 
on the mammalian genome.  Methyl groups are covalently added at the 5 carbon of the cytosine ring, 
resulting in 5-methylcytosine (5mC). 4% of mammalian DNA is composed of 5-methylcytosine at 
CpG dinucleotides (CpGs) [1].  DNA methylation plays important roles in key biological processes, 
including genomic imprinting, X-chromosome inactivation, suppression of transposable elements, and 
carcinogenesis [2, 3]. As genome wide methylation profiles associated with specific diseases are 
increasingly becoming available, interpreting these often descriptive and correlative methylome 
datasets remains a big challenge. 
 In higher eukaryotes, methylation of CpG sites, especially at promoter regions, is generally considered 
as the hallmark of gene silencing [4]. The molecular consequence of CpG methylation is generally 
believed to disrupt TF–DNA interactions either directly [5], or indirectly by recruiting sequence-
independent methylated DNA-binding proteins that occupy the methylated promoters and compete for 






Figure 2-1. Traditional View of DNA methylation effect on gene expression 
Many genes in the human genome have upstream CG-rich regions called CpG islands. DNA methylation of a 
gene's CpG island represses gene expression. Different cell types have different methylation patterns, which 
contributes to the differences in gene expression in different cell types. (Adapted from USCF SOM 
missinglink.edu).  
 
So far, only MeCP2, MBD1, MBD2, and a few zinc finger proteins have been identified as bonafide 
methylated DNA-binding proteins [7]. It is unclear whether the methylated DNA binding activity is 
widespread among different TF subfamilies. Furthermore, the transcriptional regulatory activity of 
these methylation-dependent TF–DNA interactions has not been explored. Finally, the structural basis 
of these methylation-dependent TF–DNA interactions remains elusive.  
 
Transcription is regulated by the interaction of DNA cis-regulatory sequences and trans-acting factors. 
High throughput approaches have recently been developed to study novel protein-DNA interactions 
across genomes. This has created new frontiers as well as challenges in understanding the control of 
gene expression. The Zhu lab has previously developed a large-scale, unbiased method to characterize 
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Protein-DNA Interactions (PDIs). Using a protein microarray containing the human repertoire of 
transcription factors (TFs), which includes 1321 TFs, and 210 co-factor proteins, over 40 TFs and 6 TF 
co-factors were found to bind preferentially to mCpG-carrying DNA motifs (Hu et al, 2013) [7]. Each 
TF chip was probed with one of 154 methylated DNA motifs in the presence of 10-fold excess of the 
unlabeled counterpart. Among the 47 DNA binding proteins (DBPs) that showed binding activity to 
mCpG, 15% demonstrate broad binding activity to over 50% of all methylated motifs. One 
transcription factor that showed methylation specific binding is KLF4 [7].  
 
2-2. Krupple Like Factors (KLFs)  
The krüppel-like factors (KLFs) compose a family of transcription factors that bind to GC rich regions 
of DNA to activate or repress transcription. The first human KLF was identified by Page et al. in 1987. 
The first mammalian klf gene was cloned soon after in 1993 [8]. Since then, 16 other mammalian 
KLFs have been identified and are designated KLF1-KLF17 [9]. KLFs have three highly conserved 
consecutive Cys2-His2 zinc fingers located near the carboxyl terminus of the protein that enables them 
to interact with GC-rich sequences in target gene promoters and enhancers (Figure 2-2) [10]. 
However, they have unique amino-terminal sequences that permit the transcription factors to interact 
with specific binding partners. Through transcriptional regulation of a variety of genes, KLFs regulate 
numerous cellular processes including cell growth, proliferation and apoptosis [11]. The functions of 
the 17 KLF family members are in some cases overlapping and in others widely divergent. As 
transcriptional regulators, KLFs control essential cellular processes such as proliferation, 
differentiation and migration [11]. More recently, KLFs have also been implicated in the establishment 
and maintenance of pluripotency [12, 13]. Along with these roles for KLFs in normal cells and tissues, 
important tumor suppressive and oncogenic functions have been defined for KLFs in cancer [11].  
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In general, members of the KLF family can be grouped on the basis of structural or functional 
relationships. Moreover, some members of the family are ubiquitously expressed, whereas others are 
tissue restricted, leading to the possibility of both exclusive and redundant functions for each KLF. 
Deletion of KLF2, KLF5 or KLF6, for example, is lethal in mice, which is indicative of non-redundant 
functions during development, whereas several other KLF-knockout mice are viable, which suggests 







Figure 2-2. Phylogenetic tree of the human Kruppel-like factors (KLFs) 
(A).Phylogenetic tree of the human Krüppel-like factors (KLFs). Currently, there are 17 known KLFs in 
mammals. (B). The defining feature of the KLF family is the carboxy-terminal DNA-binding domain, which 
consists of three zinc fingers that bind GC-rich DNA sequences. The rest of the amino acid sequence is 
divergent, and each KLF typically contains at least one transactivation or transrepression domain. KLF5, for 
example, as shown in the figure, consists of 457 amino acids with three zinc fingers at the C terminus and a 
transactivation domain surrounding a proline-rich motif (amino acids 324–328), which binds the E3 ubiquitin 
ligase WWP1. 
 
2-3. Krupple Like Factor 4 (KLF4)  
KLF4 was initially identified as a growth arrest-associated gene in the intestinal epithelium that 
suppresses DNA synthesis when expressed ectopically. KLF4 is a versatile transcription factor that 
regulates numerous cellular processes [15].  KLF4-mediated gene transactivation or trans-repression is 
regulated on multiple levels by modulating KLF4's status through phosphorylation, acetylation, 
methylation, and ubiquitination in a context-dependent manner [14].  KLF4 is one of four transcription 
factors rigorously described by Yamanaka that, when ectopically expressed, reprogram somatic cells to 
pluripotent stem cells [16, 17]. Depletion of KLF4 has also been shown to result in embryonic stem 
cell differentiation [12]. KLF4 can function as both an oncogene and a tumor suppressor by regulating 
cell cycle promoting genes and genes involved in apoptosis depending on the cellular context. The zinc 











Figure 2-3. Schematic of KLF4 gene 
KLF4 belongs to the family of SP/KLF factors that are characterized by three zinc finger motifs within their 
carboxyl terminal sequences. Within its amino terminus, KLF4 possess a transactivation domain (TAD) and 
adjacent to it, a repression domain, together of which determine the specificity of KLF4’s transcriptional 
regulating activity by interacting with other factors and modulating DNA binding efficiency. Two nuclear 
localization signals (NLS) have been identified in mouse KLF4. The first is directly adjacent to the most amino 
terminal zinc finger motif and the second spans the first and half of the second zinc finger domain. Mouse KLF4 
contains 483 amino acids with a predicted molecular weight of 53 kDa, and is 91% identical to human KLF4. 
Several splice variants of the human KLF4 gene have been identified in normal and cancer cells. (Adapted from: 





Mutational and structural analysis from Hu et al 2013 [7] identified R458 as the critical residue for 
DNA methylation binding and recognition. Mutating R458 to alanine abolished KLF4’s ability to bind 






Figure 2-4. KLF4's mCpG-dependent binding activity is decoupled from its binding activity to 
unmethylated motifs 
 KLF4 encodes three zinc finger DNA-binding domains at its C-terminus. Residues R458 and D460, which were 
predicted to interact with the 5-methyl group in the cytosine, are located in the zf-H2C2 domain. (Adapted from 















































































3-1. Introduction  
KLF4 plays multiple roles in normal physiology and disease. It is one of the Yamanaka factors that 
induce pluripotency in somatic cells [1]. KLF4 also functions as a cancer driver gene [2], and is 
involved in cancer stem cell maintenance [3-5]. KLF4 has also been shown to be upregulated in high-
grade brain tumors [6, 7], such as glioblastoma (GBM) [8, 9]. In addition to driving tumor malignancy, 
KLF4 can act as a tumor suppressor in distinct cellular contexts [10-12].  
Studies by Wan et al, dissected the biological function of KLF4 binding to methylated DNA in malignant 
brain tumor cells by taking advantage of the R458A mutant lacking the ability to bind to methylated DNA.  
We showed that KLF4-mCpG interaction promotes brain tumor cell migration via the transactivation of 
genes involved in cell motility pathways [13].  
 
Glioblastoma (GBM, Grade IV glioma) is one of the most devastating forms of cancer and 
characterized by highly proliferative tumor growth and intensive tumor cell infiltration into normal 
brain tissues [14, 15]. An increased understanding of the molecular mechanisms underlying the 
aggressive behavior of tumor cells and the microenvironment in which they invade could provide 
insights into novel treatment strategies for this deadly disease. The extracellular matrix (ECM) is one 
of the critical components of the tumor microenvironment and provides essential biochemical and 
mechanical cues that direct cell growth, survival, migration and differentiation [16, 17]. Cell adhesion 
to the ECM permits growth factor-dependent activation of oncogenic signals, which promotes cell 
cycle progression and cell proliferation, while also functioning as either a barrier or a movement track 
to inhibit or promote cell migration [18]. The ECM is mainly composed of fibrous proteins (e.g., 
collagen) and gel-like substance, such as glycosaminoglycans (GAGs), which are long polysaccharide 
chains with negative charges that attract water and soluble molecules including growth factors [19]. 
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GAGs are synthesized by an enzyme called UDP-glucose 6-dehydrogenase (UGDH).  In our prior 
work, we found that krÜppel-like factor 4 (KLF4) binds to methylated CpGs (mCpG) in cis-regulatory 
elements, and activates gene expression, including UGDH, in GBM cells to exert phenotypic changes 
such as increased cell migration [13]. DNA methylation at cis-regulatory regions, mostly occurring at 
the CpG dinucleotide sites, is linked to gene repression and more recently gene activation [13, 20]. 
Given the importance of extracellular matrix function, specifically GAGs, in GBM; and the fact that 
UGDH is implicated as a rate-limiting and essential step in GAG monosaccharide synthesis [21-23], 
the mCpG-dependent activation of UGDH prompts us to investigate the biological function of UGDH 
in GBM.  
GAG formation is part of glucose metabolism: glucose is converted to glucose-1-phosphate then to 
UDP-glucose (UDP-Glu), an active form of glucose, which is further converted to UDP-glucuronic 
acid (UDP-GlcA). UDP-GlcA is the indispensable precursor for the synthesis of GAGs. The enzyme 
UDP-glucose 6-dehydrogenase (UGDH) catalyzes the biosynthetic oxidation of UDP-glucose to UDP-
glucuronic acid [21, 23], which are the building blocks of GAGs including hyaluronic acid and 
proteoglycans such as brevican, versican, aggregan etc.  GAG synthesis pathways and key players are 





Figure 3-1. Schematic Illustration of GAG synthesis pathway, different GAGs and UGDH 
function in GAG Synthesis 
GAGs reside in the extracellular space providing structural support for cells, as well as promoting cell adhesion, 
motility, angiogenesis and wound healing [24, 25]. Elevated GAG formation is implicated in a variety of human 
diseases, including the progression of epithelium tumors, breast cancers and brain tumors [19, 26]. Although 
GAGs are shown to be implicated in tumor progression, decrease in the synthesis of GAG precursor UDP-
glucuronic acid in GBM biology has not been investigated. In this current work, we investigated the 
methylation-dependent regulation of UGDH, as well as the biological function of UGDH in GBM cells. These 
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3-2. KLF4-mCpG interactions activate genes involved in migration  
In our previous studies, we firmly established that KLF4 could activate transcription of >100 genes via 
a non-canonical binding activity to methylated CpG (mCpG) to promote GBM cell migration [20]. We 
observed that one third of such genes are involved in cytoskeletal organization, extracellular matrix 
formation and cell migration (Figure 3-2). To further interrogate the biological function of KLF4-
mCpG binding activity, two previously characterized tet-on inducible human glioblastoma (GBM) U87 
cell lines were used: one expressing KLF4 wild type (KLF4 WT) and the other KLF4 site-specific 
mutant (KLF4 R458A), which lacks the mCpG-dependent binding activity but retains KLF4 canonical 
binding activity [13]. Real-time PCR (RT-PCR) and ChIP-PCR were utilized to examine the 
expression of selected KLF4 downstream target genes in GBM cells. Genes activated by KLF4 WT but 




Figure 3-2. Pathway analysis by Panther of KLF4-mCpG direct targets 
Pathways analysis in GBM cells showed that many genes are involved in cytoskeletal organization, extracellular 
matrix formation, cell adhesion and migration 
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Twenty genes from our RNA-sequencing analysis [13] were selected for further studies by RT-PCR 
based on biological function, antibody availability, and association with GBM malignancy. Gene 
expression was quantified in tet-on inducible U87 KLF4 WT cells +/- Dox, and tet-on inducible U87 
KLF4 R458A cells +/- Dox (Figure 3-3A). Our results demonstrated that KLF4 WT and KLF4 R458A 
differently induced gene expression. Specifically, eleven of the twenty genes, such as neuronal guanine 
nucleotide exchange factor (NGEF), pleckstrin homology like domain family B member 2 (PHLDB2), 
RAB guanine nucleotide exchange factor (GEF) 1 (RABGEF1), and UDP-α-D-glucose 6-
dehydrogenase (UGDH), were highly induced by KLF4 WT, but not by KLF4 R458A at the mRNA 
level (Figure 3-3A), indicating that activation of these genes was dependent on mCpG-dependent 
binding of KLF4. To further confirm that the gene activation occurred via KLF4 binding to mCpGs in 
cis-regulatory regions, we performed bisulfite sequencing to examine the methylation status of the 
KLF4-binding regions of these gene based on our previous ChIP-seq data [13]. We found that nine of 
the eleven KLF4 WT-upregulated genes were associated with highly methylated regions, and some 
examples are shown in Figure 3-3B.  
 
We next performed ChIP-PCR to examine binding activity of KLF4 WT and KLF4 R458A to the cis-
regulatory regions of a subset of the nine genes, including PHLDB2, RABGEF1, NGEF and UGDH. 
An anti-KLF4 antibody that recognizes both KLF4 WT and KLF4 R458A was used to ChIP the 
chromatins in KLF4 WT and KLF4 R458A expressing cells 48-hrs post Dox induction [13]. The 
resulting ChIP-PCR data demonstrated that KLF4 WT preferentially bound to the cis-regulatory 
regions of these upregulated genes, whereas KLF4 R458A showed much weaker or no binding signals 
to the same region (Figure 3-3C). In addition, KLF4 WT increased protein expression of PHLDB2, 
RABGEF1, and UGDH in comparison to KLF4 R458A (Figure 3-3D), corroborating that these genes 
could be functional KLF4-mCp direct targets. 
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Figure 3-3. KLF4-mCpG binding activity activates genes involved in GBM cytoskeletal 
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(A) Upper panel: Western blot analysis showed KLF4 WT or KLF4 R458A expression in tet-on stable U87 
GBM cell lines upon doxycyline treatment (1 ug/ml, 48 hrs). Lower panel: Twenty putative KLF4-mCpG gene 
targets involved in cell migration pathway were picked from our previous RNA-seq studies. Real time-PCR 
(RT-PCR) revealed 11 of the 20 genes were significantly upregulated by KLF4 WT only, with no change in 
KLF4 R458A expressing cells (+Dox, 48 hr), confirming a mCpG-dependent gene activation mechanism). (B) 
Sanger bisulfite sequencing indicated DNA methylation in tested cis-regulatory regions of putative KLF4-
mCpG targets. Examples of four genes showed highly methylated KLF4 binding regions of these genes. Each 
row represents one sequenced clone; each column represents one CpG site; filled circles stand for methylation. 
(C) Confirmation that KLF4 WT but not KLF4 R458R preferentially bound to the methylated cis-regulatory 
regions of selected genes. A KLF4 antibody was used to precipitate cross-linked genomic DNA from U87 cells 
expressing KLF4 WT or KLF4 R458A. Rabbit IgG was used to control for non-specific binding. De-crosslinked 
DNA samples were served as the input for ChIP-PCR. KLF4 binding to the selected regions was enriched in 
KLF4 WT expressing cells. (D) Western blot analysis indicating increased protein expression of the selected 
targets by KLF4 WT, but not by KLF4 R458A. 
 
3-3. UGDH correlates with KLF4 expression in GBMs and is regulated by KLF4 via a DNA 
methylation-dependent mechanism 
We decided to focus on understanding the biological function of UGDH in GBM as it is an important 
enzyme for the synthesis of extracellular matrix components. We first queried the TCGA database to 
assess gene expression in tumor and non-tumor specimens, and to determine whether selected genes 
correlate with KLF4 expression and patient survival in GBM. UGDH was found to be upregulated in 
GBM samples when compared with normal brains (Figure 3-4A). UGDH expression also moderately 
correlated with KLF4 expression in GBM samples (R= 0.32, P<0.001) (Figure 3-4B). Furthermore, 




With evidence supporting UGDH was upregulated by KLF4 WT only, but not the KLF4 R458A, we 
determined whether UGDH expression is activated by KLF4 via a methylation-dependent mechanism. 
We tested the effect of 5-aza-2′-deoxycytidine (5-Aza), a potent inhibitor of DNA methyltransferase, 
on KLF4 binding to the UGDH cis-regulatory region, and on UGDH expression. Cells treated with 5-
Aza (1µmol/L) for 2 weeks had 80% fewer methylated sites in UGDH cis-regulatory regions (Figure 
3-4D). Consistent with the reduction of mCpG sites, we observed a complete loss of KLF4 WT 
binding to the UGDH cis-regulatory region in the presence of 5-Aza (Figure 3-4E). Furthermore, 5-
Aza abrogated KLF4 WT-induced UGDH upregulation by nearly 60% at both the mRNA and protein 
levels (Figure 3-4F, G). These results demonstrate that KLF4 activates UGDH transcription in a DNA 






Figure 3-4. UGDH correlates with KLF4 expression in GBM samples and is regulated via a 
mCpG dependent mechanism by KLF4 
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(A) UGDH gene expression intensity (mean) from REMBRANDT database. UGDH expression is significantly 
up-regulated in GBM samples when compared with non-neoplastic brain samples (P<0.001). (B) Pearson’s 
correlation plots of UGDH and KLF4 expression in glioma patients of mesenchymal subtype. Plots show 
positive correlation in the expression of UGDH and KLF4 (R=0.32, P < 0.001). (C) Kaplan-Meier Survival 
Plots for glioma patients based on differential gene expression of UGDH (from REMBRANT database). P<0.05, 
UGDH high n=38, median survival =10.4 months; UGDH low n=118, median survival =13.9 months). 
The probability of survival is significantly lower in samples with high UGDH gene expression compared to 
samples with low expression in GBM mesenchymal subtype (P < 0.001). (D) Upper panel: schematic of UGDH 
gene structure showing KLF4 binding site on the first intron. Lower panels: sanger bisulfite sequencing of DNA 
methylation on KLF4 binding site of UGDH gene before and after treatment with DNA methyltransferase 
inhibitor 5-Aza. Cells pretreated with 5-aza showed 80% reduction in DNA methylation. (E) ChIP-PCR showed 
KLF4 WT preferentially bound to the methylated cis-regulatory region of UGDH; 5-aza treatment decreased 
KLF4 WT binding to UGDH. (F) RT-PCR showed UGDH mRNA was significantly induced by KLF4 WT only, 
which was abrogated by 5-aza. (G) Western blot showed induction of UGDH by KLF4 WT only. Consistent 
with ChIP-PCR and RT-PCR, 5-aza treatment partially blocked UGDH induction by KLF4 WT, in keeping with 
a methylation-dependent mechanism.  
 
3-4. UGDH knockdown decreases GAG abundance and cell migration  
Given the importance of extracellular matrix on GBM progression and the relatively unknown 
functional significance of UGDH in GBM, we focused our efforts on determining the biological 
function of UGDH in GBM cells. We hypothesized that knocking down UGDH would inhibit tumor 
cell migration and proliferation, because UGDH catalyzes the reaction that generates the key precursor 
for glycosaminoglycans, building blocks for extracellular matrix components [23]. Two GBM model 
systems, U87 cells and GBM neurosphere cells HSR-GBM1A (GBM1A), were used to conduct 
UGDH loss-of-function studies. Each cell line was transfected with lentivirus containing either one of 
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the two distinct UGDH shRNAs (sh#1, sh#2). Both shRNAs induced a significant reduction (80%- 
85%) in UGDH protein in U87 (Figure 3-5A, left panel) and GBM1A cells (Figure 3-5A, right panel). 
We tested the level of the end products of UGDH, GAGs, by utilizing a polysaccharide binding dye 1,9 
dimethyl-methylene blue (DMMB). There was a substantial reduction in the abundance of cell-
associated GAGs in UGDH knockdown cells when compared to cells transfected with control shRNAs 
(e.g., 48% by sh#1, P<0.001; and 79% by sh#2 in U87 cells, P<0.001) (Figure 3-5B; left panel). 
Similar effects were observed in GBM 1A cells (Figure 3-5B; right panel). To examine the effect of 
UGDH knockdown on GBM cell migration, transwell and wound healing scratch migration assays 
were performed in 0.1% serum medium to minimize cell proliferation. Transwell assays 24 hrs after 
cell plating revealed that UGDH silencing significantly decreased the migratory ability of GBM cells 
(by ~50% in U87, P<0.01, and 30% in GBM1A cells, P<0.05) (Figure 3-5C,D). UGDH knockdown 
also decreased cell motility in wound healing assays by 25% (P<0.05) when compared to cells 
transfected with control shRNAs after 24 hrs of scratch, and by 28% after 48 hrs (P<0.05) (Figure 3-
5E,F). Supplementing the culture medium with one of the GAGs, hyaluronic acid (HA, 100 ng/ml) 
rescued migration inhibition by UGDH shRNAs (Figure 3-5G), supporting the hypothesis that the 
effect of silencing UGDH on cell migration response is GAG-dependent. To substantiate the notion 
that the decreased cell migration in UGDH knockdown cells was not due to reduced cell growth under 
the given conditions and time points, we quantified the total cell number at 48 hrs under 0.1% FBS, 








Figure 3-5. UGDH knockdown decreases GAG abundance and cell migration 
(A) U87 and HSR-GBM1A (GBM1A) cells were infected with lentivirus coding for control shRNA, UGDH 
shRNA #1 or UGDH shRNA #2. UGDH knockdown was quantified by immunoblot analysis. Both UGDH 
shRNAs decreased UGDH protein level by more than 80%. (B) Sulfated GAG (sGAG) concentration was 
quantified by DMMB assay. UGDH knockdown showed significant reduction in GAG concentration in both 
U87 (Left panel) and GBM1A cells (right panel). (C) Transwell migration assays showed significant decrease in 
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migration of UGDH knockdown U87 cells (left panel) and GBM1A cells (right panel). (D). Microphotographs 
of transwell analysis of U87 cell migratory ability of control and UGDH silenced cells. After 24 hrs, cells 
migrated on the other side on the membrane were stained with DAPI and counted 5 fields/well. (E) Wound 
healing scratch assays showed UGDH knockdown decreased migration in U87 cells. (F) Quantification of 
wound healing scratch assays showed UGDH knockdown decreased migration in U87 cells. (G). Exogenous HA 
rescued cell migration in scratch assays, in both U87 control and UGDH shRNA transfected cells.   
 
 
Figure 3-6. Cell proliferation assays for scratch assays 
 (A) Cell proliferation assays under the conditions and time course of scratch assays. Cells grown in 0.1% FCS 
for 48 hrs were counted manually. No difference in cell number was recorded, confirming an anti-migratory role 
of UGDH knockdown under the similar conditions. (B) Trypan blue staining showed that in cultures grown at 6 
and 9 days after plating, both control cells and UGDH knockdown cells had comparable percentage of cell 
death, suggesting that the reduced cell growth after long time in culture was not due to cell death. 
 
 
3-5. UGDH knockdown decreases GBM cell proliferation and clonogenicity  
Studies show that, in addition to a prominent role in migration and metastasis, GAGs can influence 
signal transduction, proliferation and differentiation [22]. We hypothesized that reduction of UGDH 
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could also influence cell proliferation. Cell counting demonstrated that UGDH knockdown inhibited 
cell proliferation by 45% and 20-50% after 9 days in U87 and GBM1A cultures, respectively (Figure 
3-7A, P<0.001). Trypan blue staining demonstrated the reduced cell growth was not due to cell death 
as both control cells and UGDH knockdown cells had comparable percentage of non-viable cells. 
Next, we examined the effects of UGDH knockdown on clonogenicity of U87 cells and the capacity 
for neurosphere formation in GBM1A cells. We found that compared to controls, reduction of UGDH 
dramatically impaired the ability of U87 cells to form colonies in soft agar (by 50-60%, P<0.001) 
(Figure 3-7B; left panel). We also observed a ~70% reduction in the neurosphere forming capacity of 
GBM neurosphere cells as compared with the controls (P<0.001) Figure 3-7B; right panel). Next, we 
analyzed cell cycle progression in U87 control and UGDH knockdown cells. Cell cycle was 
synchronized by incubating cells in 0.1% serum for 48 hrs, followed by stimulation with 10% serum 
for up to 32 hrs. Cell cycle progression was analyzed at 0, 8, 16, 24 and 32 hr post serum addition. At 0 
h, both control and UGDH knockdown cells had ~80% of cells in G1/G0 phase. After replenishing 
serum for 32 hrs, 83% of UGDH knock down cells remained in G1/G0, in comparison to only 60% in 
control cells (P<0.001, Figure 3-7C). Thus, UGDH knockdown displayed a delay in G1/G0 to S phase 
transition.  Analysis of cell cycle regulators by Western blot revealed a 65%-80% reduction in cyclin E 
and a 40-50% decrease in cyclin D1 in UGDH knockdown cells (Figure 3-7D), providing further 
evidence that UGDH loss-of-function promoted a delay in cell cycle progression, which led to 




Figure 3-7. UGDH knockdown decreases GBM cell proliferation and clonogenicity 
 (A) Cell growth curve up to 9 days after plating. Trypsinized cells were stained with Trypan blue viable cells 
were counted on the days indicated. (B) Colony formation assays showing significant decrease in anchorage 
independent clongenicity in UGDH knockdown U87 cells (right panel). For GBM neurosphere cells, equal 
numbers of viable GBM1A cells were plated and cultured for 14 days to allow neurosphere formation. 
Neurospheres (>100 µm diameter) were counted with MCID software. UGDH silencing inhibited neurosphere 
formation.  (C) Cell cycle was synchronized.  There was a delayed progression to S phase in U87 UGDH 
knockdown cells compared to controls after 32 hrs of serum replenishing. (D) UGDH silencing decreased cyclin 
D1 and E protein levels in GBM cells. (*: P < 0.05; ** P<0.01; *** P<0.001). 
 
3-6. UGDH knockdown reduces growth of GBM xenografts  
The results that UGDH knockdown dramatically decreased GBM cell growth and migration in vitro 
prompted us to hypothesize that dramatic reduction of GAGs by UGDH knockdown would alter tumor 
growth in vivo. To examine the effect of UGDH silencing on orthotropic GBM growth, we employed 
GBM1A cells that form infiltrative orthotropic xenografts in immunodeficient (SCID) mice to examine 
the effect of UGDH silencing in vivo. GBM1A cells stably expressing either control shRNA or UGDH 
shRNA#1 were implanted into the brains of SCID mice and sacrificed 50 days after implantation 
according to our previous studies using this model [27]. Coronal brain sections were stained for 
hematoxylin and eosin. Tumor size measurement demonstrated a ~65% reduction in tumor growth in 
mice implanted with UGDH shRNA transfected cells (2.0 mm3) compared to control shRNA 
transfected cells (6.0 mm3) (Figure 3-8A, P<0.001). The anti-tumor effects of UGDH inhibition could 
be explained in part by a ~25% inhibition of the tumor cell proliferation index measured by anti-Ki67 
immunohistochemical staining (Figure 3-8B, P<0.001), and ~25% inhibition of the vascular density 
index measured by anti-laminin staining, respectively (Figure 3-8C, P<0.001).  
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3-7. UGDH knockdown decreases expression of extracellular matrix proteins in GBM xenografts 
Given the evidence that UGDH knockdown inhibits GAG expression in vitro, we investigated the 
extracellular matrix components in UGDH knockdown xenografts, hypothesizing that GAG expression 
inhibited by UGDH knockdown would alter extracellular matrix formation and therefore impact tumor 
growth. Expression of brevican, a proteoglycan downstream of UGDH pathway and tenascin C, a 
glycoprotein that binds and connects proteoglycans in the ECM, was quantified by 
immunohistochemical staining of intracranial xenograft sections from control and UGDH knockdown 
tumor groups. Brevican and tenascin C staining was reduced by 40-50% in tumors harboring UGDH 
shRNA compared to control tumors as evidenced by Image J software quantification of staining 
intensity (Figure 3-8D, E, P<0.001). In vitro Western blot analysis of U87 and GBM1A cells further 
confirmed reduced brevican (50%) and tenascin C (~65%) expression in response to UGDH silencing 
(Figure 3-8F, P<0.001). These results demonstrate that UGDH knockdown decreases the expression 





Figure 3-8. UGDH knockdown inhibits GBM growth in vivo 
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 (A) Control shRNA or UGDH shRNA transfected GBM1A cells (100,000) were implanted by stereotactic 
injection to caudate/putamen of severe combined immunodeficiency mice (SCID).  Animals were sacrificed 50 
days after implantation. Hematoxylin and eosin-stained coronal brain sections (20 µm) obtained from animals 
showed dramatically decreased tumor size in UGDH knockdown groups (left panels, bar = 100 mm). Right 
panel: quantification of xenograft tumor volume shows that silencing UGDH repressed xenograft growth by 
more than 65% (6.4 in control vs 2.3 in UGDH sh#1, P < 0.001).  B.  UGDH knockdown significantly inhibited 
tumor cell proliferation by 31% as evidenced by Ki67 staining. C. UGDH loss-of-function inhibited blood 
vessel density by 25% as evidenced by laminin staining. (D, E) Xenografts with UGDH knockdown decreased 
the abundance of key extracellular matrix components tenascin C and brevican in GBM1A xenografts. (F) 
Western blots showing decreased brevican and tenascin C protein in U87 UGDH knockdown cells in vitro.  
 
3-8. UGDH is required for induction of GBM cell migration by KLF4-mCpG interactions 
Finally, we investigated the involvement of UGDH in cellular phenotype changes induced by KLF4-
mCpG interactions. In tet-on U87 and GBM1A KLF4 WT cells, we knocked down UGDH expression 
with shRNAs to generate stable cells lines. Immunoblot analysis showed an ~80% to ~90% inhibition 
of UGDH in both U87 KLF4 WT and GBM1A KLF4 WT model systems (Figure 3-9A). KLF4 
expression increased UGDH protein expression in the control shRNA transfected U87 and GBM1A 
cells as we have shown before, but failed to do so in the UGDH knockdown cell models (Figure 3-
9A). A concomitant ~40-60% increase in GAGs in both U87 and GBM 1A cells was also observed 
after KLF4 WT expression was induced. However, UGDH knockdown abolished the increased GAG 
levels induced by KLF4 (Figure 3-9B). Next, we examined the effects of UGDH knockdown on 
KLF4-mCpG mediated GBM cell migration. KLF4 WT expression increased cell migration in 
transwell and wound healing assays, while UGDH knockdown reversed these changes induced by 
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KLF4-mCpG interactions (Figure 3-9C, D). These results support that UGDH is required for cell 
migration mediated via KLF4 binding to methylated CpGs.  
 
 
Figure 3-9. UGDH is required for KLF4-mCpG dependent increase in GBM cell migration 
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(A) U87 KLF4 WT and GBM1A KLF4 WT cells were infected with lentivirus coding for control shRNA, 
UGDH shRNA #1 or UGDH shRNA #2. Cells were treated with Dox for 48 hrs before each analysis. Western 
blot showed UGDH knockdown significantly reverses KLF4 WT dependent induction of UGDH in both U87 
and GBM1A cells. (B) Sulfated GAG (sGAG) concentration in U87 and GBM1A cells expressing KLF4 WT 
was determined by DMMB assay. UGDH knockdown significantly decreased the KLF4 dependent increase in 
GAG concentration (C) UGDH knockdown significantly reversed the KLF4-dependent increase in cell 
migration in transwell assays. Cell migration was evaluated 24 hrs later by counting DAPI-stained cells. Five 
fields per well were counted. (D) U87 KLF4 WT cells harboring UGDH shRNA were treated with Dox for 5 
days till confluence. A scratch was made and cells were maintained in 0.1% FCS medium overnight. 
Microphotographs were taken 0 hr and 24 hrs after scratching. Bar = 100 um. UGDH knockdown inhibited the 
increased ability of KLF4 WT cells to migrate towards scratched area.  
 
3-9. Discussion  
Elevated glycosaminoglycan (GAG), major components in tumor microenvironment, has been shown 
to regulate multiple oncogenic pathways including tumor growth, invasion and migration [17, 19, 25]. 
Consistent with these findings, several studies have demonstrated that inhibiting GAG synthesis 
diminishes tumor growth and metastasis [24, 25, 28]. In our prior study, we found that krÜppel-like 
factor 4 (KLF4) promotes GBM cell migration by binding to methylated DNA (mCpG) and activating 
gene expression. In this study, we investigated a subset of KLF4-mCpG direct targets and focused on 
UDP-glucose dehydrogenase (UGDH), given its importance as an enzyme involved in the synthesis of 
the precursors for GAGs.  Although UGDH is implicated as a rate-limiting and essential step in GAG 
monosaccharide synthesis [21-23] the biological function of this enzyme in GBMs has not been 
explored. We demonstrate that UGDH is regulated via a methylation-dependent pathway; UGDH 
regulates cell migration and proliferation in vitro; silencing UGDH decreases levels of GAGs and 
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some key components of the extracellular matrix in vitro and in vivo, and results in inhibition of GBM 
growth. A model of UGDH’s regulation and implication in GBM biology is proposed in Figure 3-10 
 
 
 Figure 3-10. Working model of KLF4 mediated increase in UGDH leading to increased GBM 
tumor migration and invasion 
 
Expression of proteoglycan brevican and glycoprotein tenascin C, both of which are overexpressed in 
primary brain tumors as well as in experimental models of glioma, have been implicated in GBM 
progression [28-30]. In our study, cell migration was rescued by exogenous HA in UGDH knockdown 
cells, supporting the notion that the biological function of UGDH occurs via GAG production. 
Although it is not surprising that silencing UGDH expression leads to decreased tumor progression, 
our work provides a direct link between GAGs and other extracellular matrix proteins including 
tenascin C, a glycoprotein with a short carbohydrate chain. Tenascin C is shown to be elevated in the 
extracellular matrix of malignant brain tumor models and mediates tumor progression [30]. In our 
GBM models, we found that a reduction of GAGs facilitates decreased expression of tenascin C in 
vitro and in vivo, possibly via a post-translational mechanism. It has been reported that in human 
brains, the most abundant gel-like, long charge GAG, hyaluronic acid, serves as the backbone for the 
connection of other proteoglycans such as the brevican, which are further linked by tenascin C. It is 
conceivable that a decrease in glycosaminoglycan expression would disrupt the formation of these 
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complex networks, resulting in a decreased deposit of tenascin C. The exact mechanism through which 
silencing UGDH induces a decrease in tenascin C requires further detailed studies.    
 
Whereas silencing UGDH dramatically decreased tumor cell migration and proliferation in vitro, our in 
vivo UGDH knockdown xenografts showed a dramatic decrease in tumor growth, mainly via 
decreased tumor cell proliferation. Unlike our previously published studies on tenascin C [30] in which 
the tumor/normal brain interface demonstrated well-demarcated borders in tenascin C knockdown 
orthotopic xenografts, our UGDH knockdown models did not support a role for UGDH knockdown in 
tumor cell infiltration in vivo. This could be due to a moderate decrease in extracellular matrix 
components, such as brevican and tenascin C, in UGDH knockdown xenografts, as opposed to a 
complete elimination of these components in TNC knock down xenografts [30].   
 
DNA methylation, mainly at the C5 of the CpG dinucleotides, is present throughout the genome and 
more than 70% of CpGs are methylated in GBM [31, 32]. In fact, DNA hypermethylation is among the 
most commonly investigated epigenetic alterations in GBMs [32]. An increased understanding of how 
abnormal DNA methylation patterns contribute to transcription factor binding ultimately leads to 
downstream gene transcription is important for developing effective epigenetic-related therapies 
against GBM tumor progression.  In this work, the anti-proliferative and pro-migratory role of UGDH 
are shown in vitro; a DNA methylation-dependent mechanism for UGDH regulation is identified, and 
modulation of GBM cell migration via KLF4-mCpG interactions is demonstrated. While little is 
known about the epigenetic regulation of UGDH expression, this study shows for the first time that 
KLF4 up-regulates UGDH expression via a methylation-dependent manner and also increases GAGs 
in GBM cells. Since our previous studies indicated that KLF4-mCpG binding activity promotes 
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migration but not proliferation in GBM cells, we focused our efforts on studying the effect of UGDH 
knockdown on KLF4-induced GAG production and cell migration in GBM cells. 
Finally, considering the importance of the enzyme UGDH in GAG synthesis and the critical role of 
GAG in tumor growth, we provide evidence supporting the notion that UGDH could be a potential 
therapeutic target to treat GBM malignancy. Future studies with small molecular inhibitors specific for 
UDGH would test if UGDH could serve as a therapeutic target alone or in combination with other 















































































































CHROMOSOME CONFORMATION CAPTURE (3C) ANALYSIS REVEALS 
KLF4 BINDS TO METHYLATED CPG AT ENHANCER REGIONS TO 






4-1. Introduction  
Using zinc finger krueppel-like factor 4 (KLF4) as the first candidate, we investigated the function of 
TF-mCpG binding in biological relevant systems, e.g. human GBM cells, and obtained strong evidence 
that KLF4 binds to mCpG at cis-element regions and activate GBM adhesion and migration. 
Employing KLF4 site-specific mutant (KLF4R458A) that lacks KLF4 binding ability to mCpG but 
retains its binding to canonical, non-methylated CpGs, we discovered that this novel KLF4-mCpG 
interaction could activate gene expression [1]. A follow-up study aimed to determine the cellular 
function of KLF4-mCpG interactions in GBM cells [2]. Our studies revealed that KLF4 mediates brain 
tumor cell migration by binding to mCpGs in the cis-regulatory elements and activating cell motility 
gene expression, e.g. RHOC, RAC1 etc [2]. All these in-depth studies of KLF4-mCpG interactions 
focused on KLF4 binding to mCpG at promoter regions. The function of KLF4-mCpG interactions at 
enhancer regions requires more investigation.   
We also identified many other direct targets of KLF4-mCpG binding, including the Src family member 
of B Lymphocyte Kinase (BLK). The Src family of tyrosine kinases consists of non-receptor tyrosine 
kinases including LYN, LCK, HCK and BLK. Src kinases function in the signal transduction of 
multiple cellular processes including migration, adhesion, invasion, angiogenesis, proliferation and 
differentiation. BLK is primarily expressed by B lineage cells but it is also expressed in non B-lineage 
cell types such as pancreatic b cells and human thymocytes [3]. BLK is activated upon B cell receptor 
(BCR) stimulation and phosphorylates others in the BCR signaling pathway. Besides a role of BLK in 
B cell receptor signaling and B cell development, the cellular functions of BLK in brain tumors are 
poorly defined [4]. 
In the current study, we focused our studies on BLK regulation and biological function. Through 3C 
analysis, we found BLK was activated by KLF4 binding to enhancers in a methylation dependent 
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manner. In addition, we found that in genome scale, KLF4 binds to methylated enhancer regions and 
activates gene transcription. 
 
4-2. Identification of proteins regulated by KLF4-mCpG binding  
In our previous studies by Hu et al [1], KLF4 point mutation R458A was generated to study  KLF4 
binding to methylated CpG (mCpG). Compared to KLF4 wild type (KLF4 WT), KLF4 R458 loses 
KLF4 binding ability to mCpG but retains its binding to non-mCpG. The lack of binding to mCpG by 
KLF4 R458A mutant was further confirmed by our recent publication using whole genome bisulfite 
sequencing and chromatin immunoprecipitation (ChIP)-sequencing in our previously engineered 
human U87 GBM cells expressing tet-on KLF4 WT or KLF4 R458A [2]. In these models, cells 
without doxycycline treatment served as a negative control; upon doxycycline (Dox) treatment, KLF4 
WT and KLF4 R458A were induced by ~20 fold, similar to that during cancer cell reprogramming 
when challenged by growth factors [5] (Fig. 4-1A). Therefore, the distinct phenotypes and downstream 
targets driven by KLF4 WT and KLF4 R458A have been considered as biological function of KLF4-
mCpG interactions. It was critical to detect our KLF4-mCpG targets at the protein level. Therefore, we 
performed proteomics to identify protein expression changes driven by KLF4 WT and KLF4 R458A. 
 
The protein expression changes mediated by KLF4 WT and KLF4 R458A mutant were measured under 
four conditions: U87 KLF4 WT +/- Dox and U87 KLF4 R458R +/- Dox after cells being treated with 
Dox for 48 h. In all, we detected 6875 proteins (or 7008 isoforms) in our proteomics analysis. We 
compared protein expression changes in U87 KLF4 WT cells after Dox treatment with that before Dox 
treatment, and found 73 proteins were up-regulated and 37 down-regulated in KLF4 WT expressing 
cells (Fig. 4-1B). In contrast, no differentially expressed proteins were found upon KLF4R458A 
induction when we used the same cut-off as the KLF4 WT cells (data not shown). Expression levels of 
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a given protein significantly altered (up-regulated or down-regulated) by KLF4 WT, but not by 
KLF4R458A would be the putative KLF4-mCpG direct targets. With these criteria, our large-scale 
proteomics data analysis generated a total of 110 proteins differentially affected by KLF4 WT and 
KLF4 R458A mutant. To further determine if these proteins were direct targets of KLF4 binding 
activities, we examined the binding of KLF4 to the cis-regulatory regions of these proteins. In total, 39 
proteins were up-regulated by with KLF4 binding to mCpGs at either upstream/5’UTR/exon or 
predicted enhancer location in U87 cells (Fig. 4-1C). For example, our data indicated that the protein 
expression level of small GTPase RHOC was increased by KLF4 WT but not KLF4 R458A, consistent 
with our previous RNA-seq, RT-PCR and Western blot analysis [2], indicating that KLF4-mCpG 
interactions drove the transcriptional and translational activation of RHOC. Another validated KLF4-
mCpG target, UGDH was also found only up-regulated by KLF4 WT in our proteomics studies.  
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Figure 4-1. Protein Expression changes induced by KLF4 WT and KLF4 R458A in U87 cells 
A. U87 KLF4 WT and U87 KLF4 R458R cells were treated with Dox (1 ug/ml) for 48 h, Western blot analysis 
verified the induction of KLF4 WT and KLF4 R458A proteins. B. Graph of differentially expressed proteins 
regulated by KLF4 WT and KLF4 R458A. Protein samples were collected from untreated and Dox treated U87 
KLF4 WT and KLF4 R458A cells, and subjected to mass spectrometry for protein analysis. In total, expression 
of 65 proteins was altered by KLF4 WT, but not by KLF4R458A. Approximately 40 proteins were up-regulated, 
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and ~25 down-regulated by KLF4 WT only. C.  Heatmap of proteomics data with our previously published 
RNA-seq data  
 
4-3. BLK was activated by KLF4 in a mCpG-dependent manner 
In our previous studies, we used chromatin immunoprecipitation (ChIP) sequencing to search for KLF4-
mCpG binding sites, and we performed RNA-sequencing to identify gene expression changes driven by 
KLF4-mCpG interactions. By combining KLF4-mCpG binding sites and KLF4-mCpG-regulated genes, 
a list of ~130 genes were generated as direct gene targets of KLF4-mCpG [2]. From our large scale 
RNA-sequencing (published in [2]) and proteomics analysis, we noticed one of the putative KLF4-
mCpG targets, BLK, was up-regulated by KLF4 WT at both the mRNA (Fig. 4-2A) and protein level 
(Fig. 4-1C). We further validated the expression of BLK, by quantitative real time PCR (RT-PCR) and 
Western blot analysis. RT-PCR indicated that BLK mRNA level was increased ~2.2 fold upon KLF4 
WT expression for 48 h, but not changed by KLF4 R458A (Fig. 4-2B, P<0.05). Western blot analysis 
confirmed that BLK protein was significantly increased by ~3.9 fold by KLF4 WT only, but not by 
KLF4 R458A (Fig. 4-2C, P<0.001). The differential expression of BLK in KLF4 WT and KLF4 
R458A cells suggested that BLK was activated by KLF4 binding to methylated CpGs in cis-regulatory 
elements. To find out the binding sites of KLF4, we queried our KLF4 ChIP-sequencing data for BLK 
in U87 KLF4 WT and KLF4 R458A expressing cells. We found two possible binding sites for KLF4 
WT on the entire genome of the BLK gene, one at the 5’-UTR site, and the other at the 3’-UTR site 
(Fig. 4-2D). The 5’-UTR KLF4 binding site did not contain CpG sites, but the putative KLF4 binding 
site of BLK gene at 3’-UTR contained multiple mCpG sites, therefore we focused our following studies 
on the 3’UTR site. We queried KLF4 ChIP-seq data and found that this site was only bound by KLF4 
WT, but not by KLF4 R458A (Fig. 4-2E), suggesting that mCpG mediated KLF4 binding at this site. 
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Further investigation of the enhancer mark H3K27ac ChIP-seq data at the same site revealed that there 
was an enrichment of H3K27ac binding in U87 KLF4 WT expressing cells, but not in control or KLF4 
R458A expressing cells (Fig. 4-2F).  
 
 
Figure 4-2. BLK was only bound and activated by KLF4 WT, not KLF4 R458A. 
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A. RNA-sequencing data showing that BLK gene was only up-regulated by KLF4 WT, but not KLF4 R458A. B. 
Real time-PCR verified that BLK mRNA level was increased by ~2.6 fold in KLF4 WT expressing cells only. 
C. Western blot analysis showed that BLK was up-regulated ~3 fold by KLF4 WT, but not changed by KLF4 
R458A. D. KLF4 ChIP-sequencing data of BLK in U87 cells. There are two possible binding sites for KLF4 at 
the entire genomic structure of BLK, one is that the 5’-UTR site, the other one is at the 3’-UTR site.  
 
To determine if KLF4 indeed bound to the 3’-UTR site of BLK gene via mCpG-dependent mechanism, 
we performed ChIP-PCR. An antibody against KLF4 was used to precipitate genomic DNA from KLF4 
WT and KLF4 R458A expressing cells (+Dox 48h). This antibody recognized N-terminal of KLF4 and 
has been previously shown to equally precipitate KLF4 WT and KLF4 R458A as the mutated site is at 
the C-terminal of KLF4 [2]. We found that binding fragment at the 3’-UTR of BLK gene was only 
enriched in KLF4 WT expressing cells, but not in KLF4 R458A expressing cells, indicating that the 
mCpG-dependent binding activity of KLF4 was involved in BLK transcription (Fig. 4-3A). To confirm 
the methylation status of the BLK binding regions, bisulfite sequencing was performed. There was a 
100% methylation level at 3 CpG sites of the putative BLK binding site at 3’-UTR (Fig. 4-3B).   
 
To confirm that methylation at the 3’-UTR is responsible for KLF4 binding and gene activation in vivo, 
we treated the cells with the DNA methyltransferase inhibitor 5-aza, which has been previously proven 
by us to significantly decrease genome wide methylation and reverse gene expression in U87 cells [2]. 
5-Aza completely erased the methyl group at the CpG sites we tested (Fig. 4-3C). ChIP-PCR also 
indicated that 5-aza completely blocked KLF4 WT binding to the 3’-UTR of the BLK gene (Fig. 4-3D). 
RT-PCR revealed that 5-aza reversed BLK induction in KLF4 WT expressing cells (Fig. 4-3E). All 
these suggest that the methylated sites at the 3’-UTR of the BLK gene bound to KLF4 and is responsible 
for up-regulated BLK expression. 
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Figure 4-3. KLF4 bound to the enhancer region of BLK in a methylation dependent manner to 
activate gene expression 
A. Genomic DNA from U87 KLF4 WT and KLF4 R458A cells  immunoprecipitated by a KLF4 antibody and 
served as templates for PCR. The 3’UTR binding site of BLK gene amplified and was only enriched in KLF4 
WT expressing cells, not in KLF4 R458A expressing cells. Input genomic DNA served as a positive control and 
isogenic IgG negative control. B. Bisulfite sequencing analysis of the KLF4 binding site at 3’-UTR of BLK gene 
indicated that  3of 5 CpG sites were 100% methylated in U87 cells. C. U87 KLF4 WT cells were treated with 
DNA methyltransferase inhibitor 5-Aza. 5-Aza completely erased the methyl group at the CpG sites of the 
3’UTR region of BLK gene.  D. ChIP-PCR of the same 3’-UTR region in U87 KLF4 WT cells after 5-Aza 
treatment. 5-Aza abolished KLF4 WT binding to this fragment. E. RT-PCR indicated that 5-Aza reversed BLK 
induction in KLF4 WT expressing cells. 
 70 
4-4. 3C showed that KLF4 binds to the 3-D structure of BLK genome 
The putative KLF4 binding site of BLK gene at 3’-UTR contained multiple mCpG sites and more likely 
serves as an enhancer to activate gene expression. We speculate that KLF4 binds to the BLK promoter 
region at 5’-UTR and the enhancer at 3’-UTR through a chromatin loop to activate gene expression 
(Fig. 4-4A). chromosome conformation capture (3C) technique was performed to investigate whether 
KLF4 binding to methylated CpG at enhancer regions could activate gene expression. Experiments 
were performed under four conditions, U87 KLF4 WT +/- Dox and U87 KLF4 R458A +/- Dox. 
Genomic DNA from cells was cross-linked and fragmented by digesting with two enzymes: Bgl I and 
Hind III. The digested DNA fragments were ligated and served as templates for PCR. Two primers 
were designed to amplify the adjacent sites of the looped structure, the left primer spanned the end of 
5’-UTR KLF4 binding site, and the right primer spanned the beginning of 3’-UTR KLF4 binding site. A 
fragment of 298 bp PCR product was predicted if our hypothesized BLK activation model in Fig. 4A 
was correct. Indeed, PCR products that linked the 5’-UTR and 3’-UTR binding fragments with the 
corrected size (~298 bp) were detected in U87 KLF4 WT cells before Dox treatment, and increased 
after KLF4 WT induction. In contrast, there was no enrichment of this putative linked fragment in U87 
KLF4 R458A cells (Fig. 4-4B). Since the same amount of ligated DNA from each condition was used 
as the PCR template, we were able to semi-quantify a ~9.2 fold increase in PCR product of U87 KLF4 
WT expressing cells, when compared to cells before Dox treatment (Fig. 4-4C, P<0.001). Sanger 
sequencing showed that the PCR fragment sequence was a 100% match to the putative loop linked 
sequence as AATAAGCTTGC (Fig. 4-4D, E showing the linked sequence). All these data indicates 
that BLK was activated by KLF4 binding to the enhancer at 3’-UTR and forming a 3D structure with the 
promoter region at 5’-UTR.   
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We also found that KLF4 R458A did not increase the PCR production of the ligated fragment from the 
putative loop structure, indicating that methylation dependent KLF4 binding to the 3’-UTR of BLK 
genome structure is responsible for the loop formation. To corroborate this, the KLF4 WT cells were 
treated with 5-Aza before adding Dox, and we failed to amplifying the loop fragment in U87 KLF4 WT 
expressing cell under this condition (Fig. 4-4F), further supporting our hypothesis that KLF4 binds to 
mCpGs at the 3’- UTR enhancer region to activate gene expression. 
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Figure 4-4. Chromosome conformation capture (3C) showed KLF4 bound to methylated 
enhancer to activate BLK expression. 
A. Hypothesized 3D structure of BLK gene activation showing KLF4 binds to the 5’-UTR and 3’-UTR fragment 
through a chromatin loop to activate gene expression. A fragment with the size of 298 bp B. 3C was performed 
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under four conditions, U87 KLF4 WT +/- Dox and U87 KLF4 R458R +/- Dox. Cross-linked genomic DNA was 
fragmented by digesting with Bgl I and Hind III followed by ligation of adjacent fragments. A primer set was 
designed to partially match the 5’-UTR and 3’-UTR KLF4 binding sites, respectively.  same amount of template 
was used for PCR to amplify the putative linked site. Indeed we detected a PCR fragment with 298 bp that link 
the 5’-UTR and 3’-UTR binding fragment together in control cells, which was significantly increased after KLF4 
WT expression (+Dox), but not changed in KLF4 R458A expressing cells. C. Quantification of the enrichment of 
PCR product in U87 KLF4 WT and KLF4 R458A cells indicated a 4.6 fold increase in the putative linked sites in 
KLF4 WT expressing cells. E. Sanger sequencing confirmed that the PCR fragment 100% matched our putative 
loop with the linked site sequencing as shown in B. D. 5-Aza treatment in U87 KLF4 WT expressing cells 
prevented loop formation and no enrichment of PCR product was detected. 
 
4-5. BLK knockdown decreased cell migration 
BLK is a non-receptor tyrosine kinase belonging to the SRC family kinases and its known to be 
functionally involved in B-cell receptor signaling and B-cell development. To determine the biological 
function of BLK in glioblastoma (GBM) cells, we studied the loss-of-function of BLK in U87 cells by 
using two BLK shRNAs to generate cell lines with BLK knock down. Two distinct constructs of BLK 
shRNA reduced BLK expression more than 80%in U87 GBM cells (Fig. 4-5A). Cell proliferation and 
cell migration were analyzed in these cells. We found that BLK knockdown did not change cell 
proliferation and clone formation ability (Fig. 4-5B, C). In contrast, BLK knockdown significantly 
increased cell adhesion (Fig. 4-5D, P<0.01), and reduced cell migration in transwell assays (Fig. 4-5E) 
and scratch wound healing assays (Fig. 4-5F). All these suggest that methylation on enhancer regions 
dictate transcription factor binding via 3D structure formation and promote cancer cell migration. 
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Figure 4-5. Biological function of BLK in GBM cells. 
A. BLK was knockdown by ~80% in U87 cells with two distinct constructs of BLK shRNA. B. BLK knockdown 
did not change cell proliferation. C. BLK knockdown significantly reduced cell migration in transwell assays.  D, 
E. BLK down-regulation partially blocked cell migration induced by KLF4. ***: P<0.001 
4-6. Global analysis of KLF4 binding to methylated enhancer regions to activate gene expression 
We believe that KLF4 binding to mCpGs on enhancer regions to activate gene expression applied to 
many more downstream targets of KLF4-mCpG interactions. We therefore performed more 
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sophisticated data analysis by integrating KLF4 WT ChIP sequencing, whole genome bisulfite 
sequencing and the enhancer marker H3K27ac ChIP sequencing data. In our previous studies, we 
identified a total of 3890 KLF4 WT binding fragments in U87 cells. Among them 1545 were highly 
methylated after overlapping with the whole genome bisulfite sequencing data. We used the histone 
mark H3K27ac as an enhancer mark, combined the H3K27ac ChIP-sequencing data with the highly 
methylated KLF4 WT binding fragments, and found 547 putative methylated enhancer regions in U87 
cells (Fig. 4-6A). Motif analysis of the 547 fragments shown in Fig. 6B. The 6-mer CCCGCC has been 
previously identified as the motif of KLF4 binding to methylated DNA.  In total, we found 149 genes 
that could be activated by KLF4 via its binding to methylated CpG at enhancer regions. Some 
examples of these genes, e.g. UGDH, LMO7, GRIN1 and HSP90AB1, shown in Fig. 4-6C, D.   
 
Besides BLK, 3C analysis was performed to validate whether other gene targets were activated by 
KLF4-mCpG interactions at enhancer regions. Mostly, we focused on those 149 putative gene targets 
that have been shown upregulated by KLF4 WT at protein level (Fig. 4-1A). Among the targets we 
tested, we found that LMO7 and UGDH were also regulated by KLF4 binding to methylated mCpGs at 
the enhancer regions via a 3D loop formation. We observed an enrichment of the predicated ligation 
fragments by binding to KLF4 to the LMO7 (Fig. 4-6E) or UGDH (Fig. 4-6F) genes in KLF4 WT 
expressing cells. In contrast, KLF4 R458A expression did not enrich the PCR products of predicted 
ligated fragments when compared to untreated cells. A negative control was seen in IDH1 gene, there 
are two possible binding sites for IDH1 and our 3C analysis failed to amplify the putative loop 
structure based on the two sites from our ChIP-seq data (data not shown). All these suggest that our 3C 






Figure 4-6. Global Analysis of KLF4 binding to mCpGs at enhancer regions to activate gene 
expression 
A. Global analysis of KLF4 ChIP-sequencing, whole genome bisulfite sequencing and the enhancer 
marker H3K27ac ChIP-sequencing data identified 547 putative methylated enhancer regions in U87 
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cells. B. Motif analysis of the KLF4 binding of the putative enhancer regions that was not within 10 kb 
of gene transcription regions (non-promoter regions).  
4-7. Discussion  
By employing a KLF4 site-specific mutant that lacks KLF4 binding to mCpGs and chromosome 
conformation capture (3C), we found that mCpG-dependent KLF4 binding at enhancer regions 
promotes 3D structure of chromatin loop formation with promoters, thereby activating gene 
expression. Our 3C analysis also found that a couple of gene targets, including BLK, UGDH, LM07, 
were activated by KLF4 binding to mCpGs at enhancer regions, indicating that KLF4-mCpG 
interactions at enhancer regions presents an important gene activation mechanism, which has only been 
sparsely reported until now. Our work, with an emphasis on actual 3D structure formation in individual 
gene activation, support genome-wide studies showing that mCpG at enhancer regions positively 
correlates with gene activation. Furthermore, our functional study of BLK revealed that BLK is also 
involved in tumor cell migration. Thus, our study is in agreement with other works that challenges the 
traditional view that promoter CpG methylation only plays a passive role in transcriptional silencing, 
as these studies, including our own, establishes a new concept that DNA methylation plays an active 
role in transcriptional activation, and this case, at enhancer regions.  
This study is a logical extension of our previous study utilizing unique KLF4 site-specific mutagenesis 
to dissect the biological function of mCpG dependent KLF4 function in GBM cells. There are several 
technical issues that warrant discussion. First, the expression level of KLF4 protein was within 
physiological range using our dox-inducible system. For example, we have reported that KLF4 is 
upregulated ~25-fold during GBM cell reprogramming induced by growth factors [5]. Second, in our 
previous studies our whole genome bisulfite sequencing in U87 cells has unambiguously proven that 
KLF4 R458A indeed is defective in binding to mCpG motifs in vivo, corroborating with our early 
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luciferase assays showing that KLF4 R458A only bound to non-mCpG motifs. Thus, we are confident 
that the difference we saw in our current 3C analysis between KLF4 WT and KLF4 R458A is 
attributed to KLF4-mCpG interactions. Third, we used ChIP-PCR to identify differential DNA 
sequences that complex with KLF4 WT or KLF4 R458A. We are confident that the differential 
binding of KLF4 WT and KLF4 R458A represented KLF4 binding via mCpG-mediated mechanism. 
The KLF4 antibody we used recognized the N-terminal of KLF4 and therefore did not interfere with 
KLF4 R458A. In our previous ChIP-PCR studies with a positive control, we have shown that this 


























































































Materials and Methods  
Reagents and Cell Cultures   
All reagents were purchased from Sigma-Aldrich unless otherwise stated. Doxycline (Dox) was diluted 
to a concentration of 1µg/ml in cell culture medium as a working concentration.  The human 
glioblastoma (GBM) cell lines U87 were originally purchased from ATCC (Manassas, VA). GBM 
neurosphere culture (HSR-GBM1A) were originally established by Vescovi and colleagues [1] and 
further characterized by us [2-4]. Both cells lines are free from mycoplasma and authenticated with 
short tandem repeat (STR) profiling by Johns Hopkins Genetic Resources Core facility using Promega 
GenePrint 10 system (Madison, WI). U87 cells were cultured in Minimum Essential Media (MEM, 
Thermo Fisher Scientific, Grand Island, NY) supplemented with sodium pyruvate (1%), sodium 
bicarbonate (2%), non-essential amino acid (1%) and 10% fetal calf serum (FCS, Gemini Bio-
products, West Sacramento, CA). HSR-GBM1A (GBM1A) cells contain CD133+ GBM stem-like 
cells and form infiltrative orthotropic xenografts that have been extensively characterized by others 
and our group [5, 6]. GBM1A neurospheres were cultured in DMEM/F12 medium supplemented with 
epidermal growth factor (EGF) (Peprotech, Rocky Hill, NJ) and fibroblast growth factor (FGF) 
(Peprotech). Cells were incubated in a humidified incubator containing 5% CO2/95% air at 37°C, and 
passaged every 4-5 days.  
Lentiviral Transduction   
UGDH shRNA lentiviral particles were purchased from Dharmacon (Buckinghamshire, UK). UGDH 
sh#1 clone ID V2LHS-171838 and UGDH sh#2 clone ID V3LHS-412961. GBM cells were transfected 
with virus for 48 hrs prior to puromycin selection (1 µg/ml) as previously described [7]. 
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Quantitative real-time PCR 
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Mansfield, MA). After reverse transcription 
using MuLV reverse transcriptase (Applied Biosystems, Calsbad, CA) and Oligo(dT) primer, 
quantitative real-time PCR (qRT-PCR) was performed using SYBR Green PCR Mix (Applied 
Biosystems) and IQ5 detection system (Bio-Rad, Hercules, CA). Primer sequences are listed below. 
Relative gene expression was normalized to 18S rRNA.  
 
Table 3: RTPCR primers  
Gene  Primer (left) 5’-3’ Primer (right) 5’-3’ 
LIMS2 ACTGCAGCCATGTGATTGAA AGCTCCGACAGCTTCTTCAG 
LM07 TTCCCCTTCAGCTTCACAGT GCAACAGTGCTTTCGTATGG 
PHLDB2 GATCGGAACAAGCGAACATT GCGATGGGGCTACCATATAA 
S100A11 ACAGAGACTGAGCGGTGCAT CCATCACTGTTGGTGTCCAG 
S100A4 GGGTGACAAGTTCAAGCTCA CTTCCTGGGCTGCTTATCTG 
STMN1 AAAGAGAACCGAGAGGCACA TGGCCAGTACAGTCTTTGGA 
NGEF CATGCTAAAGGCGTCCTCTC TGTCCAGGATGTTGAGGATG 
VCAN TTTGGAAAGATGAAACCTCGTT AATTGTCCTTTGCTGATGAGG 
ALCAM CAGAACACGATGAGGCAGAC TCCATATTACCGAGGTCCTTGT 
ANNEX2 ATGACTCCATGAAGGGCAAG GTGTCGGGCTTCAGTCATCT 
CTNNA1 CACCATTGCAGACCATTGC GCACCACAGCATTCATCAAG 
FLNB GACCTGCTATAGCGCCATTC CTGGTTGCCTACATGCTTCA 
WDR1 GCAAGGTGGTCACAGTGTTC GGTGTGCATCTTGGATCTTG 
LGALS3 GGAATGATGTTGCCTTCCAC CTGCAACCTTGAAGTGGTCA 
KIAA1199 TCAACTATGTGGCGACCATC TGGCTTTGTGATCCTCAGTG 
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PLAT AACAGTCACCGACAACATGC GTGTACACACCCGGGACATC 
MIDN AGAAACGGCTCCGTAGAAAGG GACTTGATGTCAGGGTGGACTTC 
RABGEF1 CATAAACCGGCAACCAGCAT GGCCTGTCTTGTGGAAGGTC 
PKP3 ATTTTGACGGACTCCGAAAG ACGTCACCTTCTCCTCCAGA 
UGDH CCAGCCTTTATCTTCGATGG TCACAAATAAAAATGGCAATCTC 
 
Immunoblot and Immunocytochemistry 
Total cellular protein was extracted with radioimmunoprecipitation assay (RIPA) buffer containing protease 
and phosphatase inhibitors (Millipore, Billerica, MA) and sonicated for 15 seconds; the suspensions were 
centrifuged at 3,000 g for 10 minutes. SDS-PAGE was performed with 30-60 µg total proteins using 4% to 
12% gradient Tris-glycine gels (LI-COR Biosciences, Lincoln, NE). Western blot analysis was performed 
using the Quantitative Western Blot System, with secondary antibodies labeled by IRDye infrared dyes (LI-
COR Biosciences). Antibodies were purchased from: anti-KLF4 (Santa-Cruz, Dallas, TX); anti-RHOC (Cell 
signaling, Danvers, MA); anti-RAC1 (Cell signaling), anti-UGDH, anti- RABGEF1, anti-NGEF, anti-
Brevican (Abcam, San Francisco, CA); anti- PHLDB2 (Bethyl Labs, Montgomery, TX); anti-tenascin C 
(Millipore), anti-cyclin B1, E1 and D1 (Cell signaling, Danvers, MA) and anti-β-actin. 
For staining, GBM cells grown on chamber slides were fixed with 4% paraformaldehyde for 30 min at 
4°C and permeabilized with PBS containing 0.1% Triton X-100 for 10 min. The cells were then 
incubated with primary antibodies at 40C overnight and then incubated with appropriate corresponding 
secondary antibodies conjugated with alexa fluorescent 488 or cy3 for 1hr at room temperature. Slides 
were mounted with vectashield antifade solution containing DAPI (Vector Laboratories, Burlingame, 
CA) and observed under fluorescent microscopy. Immunofluorescent images were taken and analyzed 
using Axiovision software (Zeiss, Germany).  
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Chromatin immunoprecipitation (ChIP)-PCR 
A commercial ChIP-grade anti-KLF4 antibody (H180; Santa Cruz) recognizing the N-terminal region 
of KLF4 was used for ChIP (DNA-binding domains of KLF4 are located to the C-terminus). Tet-on 
KLF4 WT and R458A GBM cells were treated with Dox for 48 hr followed by ChIP using the anti-
KLF4 antibody and Dynabeads Protein A/G (Thermo Fisher Scientific) according to a protocol 
described previously [8, 9]. Primers targeting KLF4 binding sites were identified from previous ChIP-
Seq analysis [9]. Primers targeting promoter regions lacking KLF4 binding sites were used as a 
negative control. 
Assessment of CpG methylation status by bisulfite sequencing 
Sanger bisulfite sequencing was performed as previously described [8]. Purified genomic DNA from 
GBM cells were treated by EZ DNA Methylation-Direct Kit (Zymo Research, Irvine, CA). After 
bisulfite conversion, regions of interest were PCR-amplified using Taq polemerase. PCR products 
were cleaned up and cloned into a TA vector (Thermo Fisher Scientific). Individual clones were 
sequenced (Genewiz, Cambridge, MA) and aligned with the reference sequence. Primer sequences 
used are listed in table below 
Table 4: Bisulfite Sequencing Primers  
Gene  Primer (left) 5’-3’ Primer (right) 5’-3’ 
PHLDB2 TGTAATTTTAGTATTTTTGGGAGGT TACAATCTTAACTCATTACAACCCC 
RABGEF1 GTTTAGGTTTTTTTTGATGGTGATAG CAAACTAATCTCAAACTCCTAACCTC 
NGEF CGTTAGGGTCGTCGTAGTT CGCCTAAAAACTCCCGAAAT  




Genome-wide profiling of gene expression and KLF4 binding in GBM cells 
RNA-seq: RNAs from KLF4 WT and R458A-expressing cells (0 hr and 48 hr +Dox) was subjected to 
Illumina HiSeq next generation sequencing following the standard amplification and library 
construction protocol provided by the Johns Hopkins Deep Sequencing and Microarray Core Facility.  
Sequencing was performed using 76-base single-end reads, with 23- to 33-million reads generated 
from each sample. We first used Tophat2 to map all reads to human genome (hg19) then employed 
Cufflink to summarize the gene/transcript expression based on mapped reads. An R package, DEGseq, 
was taken to identify DEGs for p < 0.001 between 0 hr and 48 hr in KLF4 WT and R458A cells, 
respectively.  
 
Whole Genome Bisulfite Sequencing (WGBS) Analysis  
We employed the software package bismark [10] to perform WGBS analysis. First, we built bismark 
reference human genome, then mapped sequence reads onto these specific references. Two files were 
generated afterwards. The text file includes the summary about total reads, mapping efficiency, total 
methylated C’s in CpG/CHG/CHH context. The other file in the same format was used for next step to 
extract methylation. Finally, we used bismark2bedGraph followed by coverage2cytosine to achieve the 
methylated and unmethylated reads of all CpG sites. The β value was calculated for each CpG site as 
the ratio of number of methylated reads to sum over methylated and unmethylated.  
 
Motifs Analysis 
To identify methylated motifs enriched in KLF4 WT-specific peaks, we first used WGBS information 
to selected all 6-mers including mCpG (β > 0.6), then enumerated these 6-mers to compare their 
occurrence in 2733 KLF4 WT-specific peaks and all KLF4 binding peaks. The p-values were 
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calculated based on hypergeometric model to represent the significance of methylated 6-mers’ 
frequencies in KLF4 WT-specific peaks compared to all, followed by multiple-test Bonferroni 
correction. The 6-mers with p < 0.01 were selected to construct the motif logo. The package, MEME 
(Multiple EM for Motif Elicitation) [11], was used to evaluate motifs significantly over-represented in 
KLF4 shared peaks, compared to all KLF4 binding peaks.  
 
Gene Ontology Analysis 
Gene Ontology analysis [12] was performed for the 116 differential expressed genes (DEGs) up-
regulated by WT only, compared to that for total 12,824 genome-wide expressed genes (FPKM > 0.5). 
The statistical significance of the enrichment was evaluated by p-value based on hypergeometric 
distribution model. The p-values were then adjusted by multiple-test correction via false discovery rate 
(FDR). A cutoff of FDR < 0.05 was used to identify significantly enriched GO terms. 
 
Chromatin immunoprecipitation (ChIP)-seq 
 A commercial ChIP-grade anti-KLF4 antibody (H180; Santa Cruz) recognizing the N-terminal region 
of KLF4 (DNA-binding domains of KLF4 are located to the very C-terminus) was used for ChIP. Tet-
on KLF4 WT and R458A cells were treated with Dox for 48 hr followed by ChIP using the anti-KLF4 
antibody and Dynabeads Protein A/G (Thermo Fisher Scientific) according to a protocol described 
previously [13]. DNA library construction and sequencing was performed at Johns Hopkins Deep 
Sequencing and Microarray Core Facility. The antibodies used for ChIP experiments were as follows: 
anti-KLF4 (Santa Cruz, H-180, sc-20691); anti-H3K27ac (Abcam, ab4279) [14]; anti-H3K27me3 
(Millipore, 07-449) [14] and anti-H3K9me3 (Abcam, ab8898) [14].  
KLF4 ChIP-Seq data were mapped by Bowtie2, followed by MACS 1.4 being used to call peaks with 
cutoff of p < 1E-5. We first obtained binding peaks for KLF4 WT and R458A, respectively. The peaks 
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identified for both KLF4 WT and R458A at the same locus were referred as shared KLF4 binding 
peaks. Then we used KLF4 WT as foreground and R458A as background control to call peaks again. 
The new peaks were marked as KLF4 WT-specific ChIP peaks, only if they were not overlapped with 
shared ones which had been already identified. Same approach was used to obtain R458A specific 
binding peaks for which the foreground was KLF4 R458A ChIP-Seq data compared to the background 
of KLF4 WT ChIP-seq data. 
We utilized MACS2 to recognize broad peaks of H3K27ac based on their ChIP-Seq data mapped by 
Bowtie2. The cutoff of broad peak call was q < 0.1. The same procedure as that for KLF4 ChIP-Seq 
was taken to distinguish H3K27ac peaks at 0 hr only, at 48 hr only, or shared at both 0 hr and 48 hr, for 
KLF4 WT and R458A, respectively. 
 
Quantitative measurement of glycosaminoglycans (GAG)  
The quantity of GAG was determined using the 1,9 dimethyl-methylene blue (DMMB) binding 
method with modifications as described by Barbosa et al [15]. Briefly, the cells were digested with 
0.2% papain in reaction buffer consisting of 0.1 M NaH2PO4, 5 mM Na2-EDTA, and 5 mM cysteine–
HCl pH 6.0, at 60 °C for 6 h. Total cell lysates were concentrated and adjusted to a concentration of 
0.1 mg protein in 50 µl before mixing with 200 µl of DMMB solution (40 mM glycine, 40 mM NaCl, 
9.5 mM HCl, and 0.0016% DMMB, pH 3.0) in each well of a 96-well microtiter plate. The absorbance 
was immediately recorded at 525 nm using a plate reader (Perkin Elmer, Waltham, MA). Serial 
dilutions of shark chondroitin-6-sulphate, ranging from 5 to 25 µg/ml, were used to establish a standard 
curve, and duplicate wells with 50 µl of papain digestion buffer were used as blanks. Sample 
concentrations were calculated using linear regression of the standard curves. 
Transwell migration assay    
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Cell migration assays were performed using transwell chambers as we previously described [7, 16]. The 
upper chamber medium consisted of either neurosphere cell culture medium without EGF/FGF or U87 cell 
media without FBS, and the lower chamber medium consisted of DMEM with 10% FBS. After 4-24 hours, 
cells that had migrated through the filter were fixed with Diff-Quick kit (Thermo Fisher Scientific). Cells on 
the upper side of the transwells were gently wiped off with Q-tips. Cells migrating through the filter were 
stained with 4'-6-Diamidino-2-phenylindole (DAPI). Migration was quantified by counting cells on five 
randomly selected fields per transwell in at least three independent experiments [16].  
 
Scratch Assay  
GBM cells were grown under 10% FCS medium in 35 mm dishes until confluent. Several scratches were 
created using a 10 µl pipette tip through the confluent cells. Dishes were washed with PBS for 3 times and 
cells were grown in 0.1% FCS medium for 24-48 hr. Phase contrast pictures were taken at different time 
points. The width of the scratch was measured and areas of wound healing were measured and quantified 
using ImageJ.  
 
Neurosphere formation assays 
Viable cells (2 x 103/well or 2 × 104/well) were cultured in 48-well or 6-well plates, respectively. After 7-14 
days, neurospheres were fixed in medium with 1% agarose, stained with 1% Wright stain solution and 
counted by computer-assisted morphometry (MCID software, Cambridge, UK) by measuring the number of 
neurospheres (>50 µm or >100 µm in diameter, as indicated) in three random fields per well. 
 
Colony formation Assay  
 Anchorage-independent tumor cell proliferation was assessed by colony formation in soft agar. UGDH 
knockdown U87 cells or control-transfected cells were plated 10,000 cells per well in 0.5% agarose medium 
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on top of regular medium containing 1% agarose and incubated for 2 weeks. The cells were stained blue 
with 1% Wright stain solution, and the number of colonies larger than 100µm in diameter were determined 
by computer-assisted image analysis MCID.  
 
Cell Cycle Analysis 
Cell cycle was analyzed by flow cytometry on a FACSCalibur (Becton-Dickinson, Mountain View, CA) 
[17]. After plating in normal medium overnight, U87 cells were synchronized by changing into 0.1% FCS 
medium for 48 hrs followed by stimulation with 10% FCS for the indicated time points.  To harvest, cells 
were trypsinized and dissociated by pipetting, fixed with 75% ethanol at 4 °C for 30 min. Cells were then 
incubated with DNase-free RNase at 37 °C for 30 min followed by propidium iodide (100 ng/ml) for 1 h at 
37 °C. The percentage of cells at each cell-cycle phase (G1/G0, S and G2/M) was analyzed using CellQuest 
software (Becton-Dickinson). 
 
Intracranial tumor implantation  
All animal protocols were approved by the Johns Hopkins School of Medicine Animal Care and Use 
Committee. SCID immunodeficient mice received 10,000 viable neurosphere cells in 2 µL PBS by 
stereotactic injection to the right caudate/putamen (AP = 0 mm, ML = −2.5 mm, DV = −3.0 mm). 
After 7 weeks, mice were sacrificed and perfused with 4% paraformaldehyde; the brains were removed 
for histological analysis. Tumor sizes were quantified by measuring maximum tumor volume on 
hematoxylin and eosin–stained brain coronal sections using computer-assisted morphometry (MCID 
software) and then applying the formula Volume = (square root of maximum cross-sectional area)3 [6]. 
The primary antibodies used for immunofluorescent staining are the following: monoclonal anti-Ki67 




Chromosome Conformation Capture (3C) 
U87MG cells were cultured in 15 cm plates to 80% confluence and were fixed with 1% formaldehyde.  
The nuclear fraction was isolated using a lysis buffer containing 10mM Tris HCl pH 8, 10 mM NaCl, 
0.2% NP40 and a protease inhibitor cocktail (Roche). DNA samples were digested with 375 units of 
HindIII and BgI (NEB) and ligated using T4 DNA ligase (NEB). Samples were then digested with 
Proteinase K (Qiagen), phenol chloroform extracted and ethanol precipitated prior to PCR analysis. 
Unligated and ligated samples were analyzed on an agarose gel and a control PCR was performed to 
confirm successful ligation using control primers. 
 
Statistical analysis 
Statistical analysis was performed using Prizm software (GraphPad, La Jolla, CA, 
www.graphpad.com). Post hoc tests included the Students T-test and Tukey multiple comparison tests 
as appropriate. All in vitro experiments reported here represent at least three independent replications. 
All data are represented as mean value ± standard error of mean (S.E.); significance was set at 

























































Conclusion   
The role of DNA methylation in gene expression has previously been described as a repressed mark by 
disrupting transcription factor (TF)-DNA interactions directly or indirectly via the recruitment of 
methyl-CpG-binding domains (MBD). This traditional view has been challenged by several 
discoveries. First, a handful of TFs, especially C2H2 zinc finger proteins, were anecdotally identified 
to specifically bind to methylated DNA sequences [1-4]. Second, earlier in 2013, Mann et al using 
methylated-CpG microarrays found that two out of 12 basic leucine zipper TFs bind to mCpG-
containing DNAs [5]. Third, a mass spectrometry-based screening approach has revealed that some 
proteins specifically bind to methylated DNA [6]. Finally, we have employed a protein microarray-
based approach and found that 42 human TFs, including KLF4, preferentially recognize mCpG-
containing DNA motifs [7]. Moreover, specific mCpG-dependent TF-DNA interactions were found to 
transactivate downstream gene expression. All these findings point out that some TFs might serve as 
“epigenetic readers” and regulate gene expression and cell phenotypes in a methylation-dependent 
manner. All this suggests that current dogma regarding DNA methylation misses an important 
dimension of the epigenetic landscape by ignoring mCpG-dependent TF-DNA interactions. The 
biological function of such TF-mCpG binding is also largely unknown. 
Using zinc finger krueppel-like factor 4 (KLF4) as the first candidate, we investigated the 
function of TF-mCpG binding in biological relevant systems, e.g. human GBM cells, and obtained 
strong evidence that KLF4 binds to mCpG at cis-element regions and activate GBM adhesion and 
migration. Employing KLF4 site-specific mutant (KLF4R458A) that lacks KLF4 binding ability to 
mCpG but retains its binding to canonical, non-methylated CpGs, we discovered that this novel KLF4-
mCpG interaction could activate gene expression. We performed follow up studies aimed at 
determining the cellular function of KLF4-mCpG interactions in GBM cells. Our studies revealed that 
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KLF4 mediates brain tumor cell migration by binding to mCpGs in the cis-regulatory elements and 
activating cell motility gene expression, e.g. RHOC, RAC1 etc.  
The mechanism adopted by brain tumor migration/invasion is an intricate program that recalls what 
takes place in carcinoma cells during metastasis initiation. Yet, no cancer driver genes have been 
implicated in tumor metastasis [8], suggesting that other mechanisms, including epigenetic regulation, 
play a role in tumor metastasis. DNA methylation-mediated gene silencing has been shown to regulate 
tumor cell migration and invasion [9-11]. Clinical studies from human brain tumor samples indicate 
that IDH1 mutated gliomas are relatively more invasive than IDH1 wild-type gliomas [12, 13], 
supporting an active role for DNA methylation in GBM invasion. We identified and dissected the 
mCpG-dependent activation of cell motility genes, including RHOC, RAC1 and UGDH, in GBM cells. 
All these in-depth studies of KLF4-mCpG interactions focused on KLF4 binding to mCpG at promoter 
regions.  
In summary, our studies promise to significantly advance our understanding of epigenetic 
mechanisms in tumor biology, which will greatly expand the epigenetic landscape in a novel direction. 
Determining DNA methylation-mediated gene transactivation mechanisms at promoter and enhancer 
regions and their impact on GBM migration/invasion would create a totally new dimension for 
interpreting current genome-wide methylation data in cancer. This work will provide a roadmap to 
studying this novel gene regulatory mechanism in other cancer subtypes, as well as characterizing 
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